

Vertigo Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Segmented By Type (Peripheral vertigo, Central vertigo), by Distribution Channel (Offline, Online), by region, and Competition

<https://marketpublishers.com/r/VC9C4A5D8529EN.html>

Date: November 2023

Pages: 88

Price: US\$ 4,900.00 (Single User License)

ID: VC9C4A5D8529EN

Abstracts

Global Vertigo Drugs Market has valued at USD 1.10 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.20% through 2028. Vertigo is a medical term used to describe a specific type of dizziness characterized by the sensation of spinning or a spinning motion when a person is stationary. It is often described as a false sense of movement, where the person feels as if they or their surroundings are rotating or moving when there is no actual motion occurring. Vertigo is different from general dizziness or lightheadedness, where individuals may feel unsteady or off-balance without the spinning sensation. Vertigo typically involves the feeling of spinning or whirling, either of oneself or the environment. This sensation can be mild to severe and may last for seconds to minutes or even hours. Many people with vertigo experience nausea and vomiting, especially when the spinning sensation is severe. Vertigo often leads to balance issues and difficulty maintaining proper posture, which can result in falls or unsteadiness. The treatment of vertigo depends on its underlying cause. Treatment options may include medications, vestibular rehabilitation therapy, dietary modifications (in the case of Meniere's disease), or surgical interventions in severe cases.

Increased awareness about vertigo and vestibular disorders among both healthcare professionals and the public can lead to earlier diagnosis and treatment, driving demand for vertigo drugs. An aging population is more susceptible to vertigo and related conditions. As the global population continues to age, there is a higher prevalence of vertigo, creating a larger patient pool for vertigo drugs. Advancements in diagnostic

tools and treatment modalities, such as vestibular testing equipment and minimally invasive surgical techniques, can boost the demand for vertigo drugs as part of comprehensive treatment plans. The willingness of individuals and healthcare systems to invest in healthcare services and medications, including vertigo drugs, contributes to market growth. The growth of telemedicine and remote monitoring services has made healthcare more accessible to patients with vertigo, facilitating diagnosis and treatment. Vertigo often occurs alongside other medical conditions, such as hypertension or diabetes. Treating these comorbidities can involve vertigo drugs, contributing to market growth.

Key Market Drivers

Technological Advancements

Researchers are continually working to develop new drugs that target the underlying causes of vertigo more precisely. These innovations can result in medications with fewer side effects and improved treatment outcomes. Advancements in biotechnology have led to the development of novel drug delivery systems. These systems can provide sustained release of medications, ensuring a consistent therapeutic effect over time and potentially reducing the frequency of drug administration. Genomic research allows for personalized medicine approaches in the treatment of vertigo. By analyzing a patient's genetic profile, healthcare providers can tailor drug therapies to individual genetic characteristics, potentially enhancing treatment efficacy. Technology-assisted vestibular rehabilitation programs are becoming more common. These programs use virtual reality (VR) and computer-based exercises to help patients improve their balance and reduce vertigo symptoms. Advanced diagnostic tools, such as video-nystagmography (VNG) and vestibular evoked myogenic potentials (VEMP) testing, provide more accurate assessments of vestibular function. These technologies aid in the precise diagnosis of vertigo causes, allowing for targeted treatment approaches. Telehealth platforms enable remote consultations with healthcare providers, allowing patients to receive timely assessments and treatment recommendations without the need for in-person visits. Remote monitoring devices can track patient progress and compliance with treatment plans.

Mobile applications (apps) designed to help individuals manage vertigo symptoms are increasingly available. These apps may provide exercises, self-assessment tools, and medication reminders to improve patient outcomes. High-throughput screening platforms and computational modeling have accelerated drug discovery processes, leading to the identification of potential vertigo drug candidates more efficiently. 3D

printing technology can be used to create customized vestibular rehabilitation tools and devices, enhancing the precision and effectiveness of treatment. AI and machine learning algorithms are being employed to analyze large datasets of patient information and clinical trials data. This analysis can help identify trends, predict treatment responses, and improve treatment strategies for vertigo. Minimally invasive surgical techniques, such as endoscopic ear surgery, have become more refined with the aid of advanced imaging and navigation systems. These technologies allow for precise surgical interventions in cases where drug therapy is insufficient. IoT (Internet of Things) devices and smart pill containers enable the remote monitoring of medication adherence. Healthcare providers can receive real-time data on patient medication usage, ensuring compliance with treatment plans. This factor will help in the development of the Global Vertigo Drugs Market.

Increasing Aging Population

As people age, they are more likely to experience vertigo and vestibular disorders. Conditions like Meniere's disease, benign paroxysmal positional vertigo (BPPV), and vestibular neuritis become more common with age, leading to a higher demand for drugs to manage these conditions. Older adults often have other health conditions, such as hypertension, diabetes, or cardiovascular diseases, that can contribute to or exacerbate vertigo. Managing these comorbidities may involve the use of vertigo drugs. The vestibular system, responsible for balance and spatial orientation, tends to decline with age. This can result in an increased risk of falls and injuries due to dizziness and vertigo, prompting the need for medications to alleviate symptoms.

Vertigo can significantly impact the quality of life for older adults, affecting their ability to engage in daily activities and reducing their independence. Effective vertigo drugs can help improve their quality of life by managing symptoms. Older adults are more likely to seek medical intervention for health issues, including vertigo. Healthcare providers may prescribe medications to alleviate vertigo symptoms and enhance the overall well-being of older patients. An aging population tends to have more frequent interactions with healthcare providers. During these visits, vertigo symptoms may be discussed, leading to diagnosis and treatment with vertigo drugs. The economic impact of untreated or poorly managed vertigo in older adults, including hospitalization and rehabilitation costs, can drive the healthcare system to invest in effective pharmaceutical solutions. Longer life expectancy means that older adults are living longer with a higher likelihood of experiencing vertigo. As a result, the demand for vertigo drugs is expected to continue to rise in aging populations. The pharmaceutical industry is increasingly focusing on developing drugs specifically tailored to the needs of the elderly population, including

those with vertigo and balance disorders. This factor will pace up the demand of the Global Vertigo Drugs Market.

Rising Awareness and Education

Increased awareness of vertigo symptoms and their potential causes prompts individuals to seek medical attention earlier. Timely diagnosis allows healthcare providers to recommend appropriate treatments, including vertigo drugs, to manage the condition effectively. Improved awareness helps reduce delays in seeking treatment for vertigo. Since many vertigo conditions can be episodic or progressive, early intervention with drugs can alleviate symptoms and prevent the condition from worsening. Education about vertigo empowers individuals to adopt self-care strategies and lifestyle modifications to manage their symptoms. In some cases, healthcare providers may recommend over the counter or non-prescription vertigo drugs, and increased awareness ensures patients are more likely to follow these recommendations. Greater awareness of vertigo and its associated risks can encourage individuals, especially those in higher-risk groups, to schedule regular medical check-ups. During these visits, healthcare providers may prescribe vertigo drugs if needed.

Awareness campaigns can help reduce the stigma associated with seeking medical help for vertigo and vestibular disorders. Individuals are more likely to seek treatment if they understand that vertigo is a medical condition that can be managed with drugs and other therapies. Informed patients and advocacy groups can raise awareness about vertigo, advocate for research funding, and push for better access to effective drugs and treatments. This can lead to improvements in healthcare policies and services related to vertigo. Education about the importance of adhering to prescribed treatment plans, including taking vertigo drugs as directed, can result in better patient compliance and treatment outcomes. Increased awareness benefits healthcare professionals as well. It ensures that they are well-informed about the latest developments in vertigo diagnosis and treatment, including the availability of new drugs. As awareness grows, there may be increased interest and investment in research and innovation related to vertigo drugs. This can lead to the development of more effective and targeted medications. Awareness campaigns at the national and international levels can be instrumental in addressing vertigo as a public health concern. These initiatives may include education about the availability of drugs and treatment options. Informed patients are more likely to engage in shared decision-making with their healthcare providers, leading to personalized treatment plans that may include vertigo drugs tailored to their specific needs. This factor will accelerate the demand of the Global Vertigo Drugs Market.

Key Market Challenges

Side Effects and Safety

The vestibular system is intricate and finely balanced. Drugs that affect the vestibular system can have unintended consequences, including side effects that impact balance, coordination, and overall well-being. People may react differently to medications. What works well for one individual may cause adverse effects in another. Finding the right balance between efficacy and safety can be challenging. Vertigo drugs that cause dizziness, drowsiness, or impair cognitive function can increase the risk of falls and injuries, particularly among older adults who are already at a higher risk of balance-related accidents. Some patients with vertigo may be taking other medications for coexisting medical conditions. Drug interactions can occur, leading to unexpected side effects or reduced drug efficacy. In cases of chronic or recurrent vertigo, individuals may need to take medications for extended periods. The long-term safety of these drugs becomes a concern, as the risk of cumulative side effects may increase. The side effects of vertigo drugs can negatively impact a patient's quality of life. For example, persistent dizziness or nausea resulting from medication can be debilitating and lead to treatment non-compliance. If patients experience unpleasant side effects from vertigo drugs, they may be less likely to adhere to their treatment regimen, reducing the effectiveness of the therapy. Even after a drug is approved and, on the market, ongoing surveillance is necessary to identify and address any previously undiscovered safety concerns. This includes monitoring real-world side effects and adverse events reported by patients and healthcare professionals.

Patient Adherence

Some vertigo conditions may require complex treatment regimens that involve multiple medications, exercises, and lifestyle modifications. Patients may find it challenging to follow these regimens consistently. The side effects of vertigo drugs can be unpleasant or debilitating. Dizziness, nausea, fatigue, or cognitive impairment are common side effects that can discourage patients from taking their medications as prescribed. Vertigo, especially when associated with chronic conditions like Meniere's disease, may require long-term or lifelong treatment. Patients may become fatigued with ongoing medication management.

Vertigo symptoms can be episodic, meaning that patients may only experience vertigo attacks periodically. During symptom-free periods, patients may be less motivated to continue taking medications, potentially leading to non-adherence. Patients may not

fully understand the importance of adhering to their treatment plans, the potential consequences of non-adherence, or how to properly take their medications. Anxiety, depression, and the psychological impact of living with a chronic condition like vertigo can affect patient motivation and adherence. Limited health literacy can hinder a patient's ability to comprehend treatment instructions, leading to unintentional non-adherence. The cost of medications and access to healthcare services can influence patient adherence. Some patients may not be able to afford their prescribed drugs or may face barriers in accessing healthcare providers. Stigma related to vertigo, or the use of medications can discourage patients from adhering to their treatment plans, particularly if they are concerned about social perceptions. Cultural beliefs and practices can influence a patient's willingness to adhere to prescribed treatments. Some cultures may have traditional remedies or beliefs about the causes of vertigo that conflict with Western medical treatments.

Key Market Trends

Personalized Medicine

Personalized medicine, also known as precision medicine, involves tailoring medical treatments, including drug therapies, to individual patients based on their unique characteristics, such as genetics, physiology, and lifestyle. Advances in genomics have allowed for genetic profiling of patients with vertigo and vestibular disorders. Identifying specific genetic markers associated with certain forms of vertigo can help healthcare providers prescribe drugs that are more likely to be effective for that individual. Researchers are working to identify specific biomarkers in patients with vertigo that can predict their response to different drugs. This enables a more targeted approach to drug therapy. Based on genetic or biomarker information, healthcare providers can select the most appropriate drug therapy for a patient. This approach minimizes trial-and-error in finding the right treatment and reduces the risk of side effects. Personalized medicine also extends to dosing. Some individuals may metabolize drugs differently, requiring personalized dosages to achieve the desired therapeutic effect while minimizing side effects. By selecting drugs and dosages based on individual characteristics, personalized medicine aims to reduce the occurrence of adverse events and side effects, improving patient safety and comfort. Tailoring treatments to a patient's specific condition and genetic makeup can lead to improved treatment efficacy. Patients are more likely to experience symptom relief with drugs selected specifically for their needs. Personalized medicine enhances patient satisfaction by offering treatments that are more likely to be effective. This can lead to better treatment compliance and improved quality of life.

Segmental Insights

Type Insights

In 2022, the Global Vertigo Drugs Market largest share was held by peripheral vertigo segment and is predicted to continue expanding over the coming years. Peripheral vertigo, which is often caused by issues in the inner ear, such as benign paroxysmal positional vertigo (BPPV) or Meniere's disease, tends to be more common than central vertigo. The higher prevalence of peripheral vertigo conditions could drive a larger market share for drugs targeting these specific disorders. Some forms of peripheral vertigo, such as BPPV, can be effectively treated with medications or maneuvers. This may lead to a greater emphasis on drug development and treatments for peripheral vertigo in the pharmaceutical industry. Peripheral vertigo conditions are often more recognizable and easier to diagnose than central vertigo, which may result in more individuals seeking treatment and pharmaceutical solutions for their peripheral vertigo symptoms. Pharmaceutical companies may have made significant advancements in the treatment of peripheral vertigo conditions, leading to more effective drugs and therapies, which in turn could boost market share. Patients with peripheral vertigo may have a higher demand for pharmaceutical treatments due to the discomfort and disruption caused by their symptoms. This demand can influence market dynamics. Healthcare providers may prescribe drugs more frequently for peripheral vertigo than for central vertigo, further contributing to the market share of this segment. The pharmaceutical industry may have focused more on developing drugs for peripheral vertigo because of its higher prevalence and the potential for successful treatment outcomes.

Distribution Channel Insights

In 2022, the Global Vertigo Drugs Market largest share was held by Offline segment in the forecast period and is predicted to continue expanding over the coming years. pharmaceutical distribution, especially for prescription medications used to treat vertigo, is subject to strict regulatory oversight in many countries. Offline distribution channels, such as physical pharmacies and healthcare providers, are more likely to adhere to these regulations, which can build trust among patients and healthcare professionals. Many vertigo drugs require a prescription from a healthcare provider. This necessitates an offline consultation with a doctor or specialist, who can then prescribe the appropriate medication. Patients may prefer this method of obtaining prescriptions and medications due to the professional guidance provided. Patients with vertigo often require consultations with healthcare professionals to diagnose the underlying cause of

their symptoms accurately. These consultations may take place in-person, leading to prescriptions issued through offline channels. Health insurance often covers medications prescribed by healthcare providers. Patients may prefer to use offline distribution channels to ensure that their prescriptions are processed correctly and covered by their insurance plans. Physical pharmacies and healthcare institutions have a long-established presence in healthcare systems. Patients may have more trust and confidence in these offline distribution channels, perceiving them as reliable sources for medications. Patients may value the face-to-face interaction with healthcare professionals when discussing their vertigo symptoms and treatment options. This personal interaction can influence the choice of offline distribution channels.

Regional Insights

The North America region dominates the Global Vertigo Drugs Market in 2022. North America, particularly the United States and Canada, boasts a highly developed and sophisticated healthcare infrastructure. This infrastructure includes state-of-the-art medical facilities, research institutions, and a robust pharmaceutical industry, all of which contribute to advancements in vertigo drug development and treatment. There is a relatively high prevalence of vertigo and related vestibular disorders in North America. This prevalence, along with an aging population, drives the demand for effective vertigo treatments, leading to a larger market for vertigo drugs. North America is at the forefront of technological advancements in healthcare. Innovative diagnostic tools and treatment modalities for vertigo, such as advanced vestibular testing equipment and minimally invasive surgical techniques, are more readily available in this region. The region is a hub for pharmaceutical research and development. Leading pharmaceutical companies and research institutions in North America invest heavily in developing new vertigo drugs and therapies, which contributes to the growth of the market.

Key Market Players

Amneal Pharmaceuticals Inc.

Endo International Plc

Epic Pharma LLC

F. Hoffmann La Roche Ltd.

GlaxoSmithKline Plc,

Intas Pharmaceuticals Ltd.

Jubilant Pharmova Ltd.

Lupin Ltd.

Novartis AG

Otonomy Inc.

Pfizer Inc.

Report Scope:

In this report, the Global Vertigo Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vertigo Drugs Market, By Type:

Peripheral vertigo

Central vertigo

Vertigo Drugs Market, By Distribution Channel:

Offline

Online

Vertigo Drugs Market, By region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

South Korea

Australia

Japan

Europe

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Vertigo Drugs Market.

Available Customizations:

Global Vertigo Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL VERTIGO DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Type (Peripheral vertigo, Central vertigo)
 - 5.2.2. By Distribution Channel (Offline, Online),
 - 5.2.3. By Region

- 5.2.4. By Company (2022)
- 5.3. Market Map

6. ASIA PACIFIC VERTIGO DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Type
 - 6.2.2. By Distribution Channel
 - 6.2.3. By Country
- 6.3. Asia Pacific: Country Analysis
 - 6.3.1. China Vertigo Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Type
 - 6.3.1.2.2. By Distribution Channel
 - 6.3.2. India Vertigo Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Type
 - 6.3.2.2.2. By Distribution Channel
 - 6.3.3. Australia Vertigo Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Type
 - 6.3.3.2.2. By Distribution Channel
 - 6.3.4. Japan Vertigo Drugs Market Outlook
 - 6.3.4.1. Market Size & Forecast
 - 6.3.4.1.1. By Value
 - 6.3.4.2. Market Share & Forecast
 - 6.3.4.2.1. By Type
 - 6.3.4.2.2. By Distribution Channel
 - 6.3.5. South Korea Vertigo Drugs Market Outlook
 - 6.3.5.1. Market Size & Forecast
 - 6.3.5.1.1. By Value

- 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Type
 - 6.3.5.2.2. By Distribution Channel

7. EUROPE VERTIGO DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Type
 - 7.2.2. By Distribution Channel
 - 7.2.3. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. France Vertigo Drugs Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Type
 - 7.3.1.2.2. By Distribution Channel
 - 7.3.2. Germany Vertigo Drugs Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Type
 - 7.3.2.2.2. By Distribution Channel
 - 7.3.3. Spain Vertigo Drugs Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Type
 - 7.3.3.2.2. By Distribution Channel
 - 7.3.4. Italy Vertigo Drugs Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Type
 - 7.3.4.2.2. By Distribution Channel
 - 7.3.5. United Kingdom Vertigo Drugs Market Outlook
 - 7.3.5.1. Market Size & Forecast

- 7.3.5.1.1. By Value
- 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Type
 - 7.3.5.2.2. By Distribution Channel

8. NORTH AMERICA VERTIGO DRUGS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Type
 - 8.2.2. By Distribution Channel
 - 8.2.3. By Country
- 8.3. North America: Country Analysis
 - 8.3.1. United States Vertigo Drugs Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Type
 - 8.3.1.2.2. By Distribution Channel
 - 8.3.2. Mexico Vertigo Drugs Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Type
 - 8.3.2.2.2. By Distribution Channel
 - 8.3.3. Canada Vertigo Drugs Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Type
 - 8.3.3.2.2. By Distribution Channel

9. SOUTH AMERICA VERTIGO DRUGS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Type

- 9.2.2. By Distribution Channel
- 9.2.3. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Vertigo Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Type
 - 9.3.1.2.2. By Distribution Channel
 - 9.3.2. Argentina Vertigo Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Type
 - 9.3.2.2.2. By Distribution Channel
 - 9.3.3. Colombia Vertigo Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Type
 - 9.3.3.2.2. By Distribution Channel

10. MIDDLE EAST AND AFRICA VERTIGO DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Type
 - 10.2.2. By Distribution Channel
 - 10.2.3. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Vertigo Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Type
 - 10.3.1.2.2. By Distribution Channel
 - 10.3.2. Saudi Arabia Vertigo Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast

- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Type
 - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Vertigo Drugs Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Type
 - 10.3.3.2.2. By Distribution Channel

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. GLOBAL VERTIGO DRUGS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product

15. PESTLE ANALYSIS

16. COMPETITIVE LANDSCAPE

- 16.1. Amneal Pharmaceuticals Inc.

- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
- 16.2. Endo International Plc,
 - 16.2.1. Business Overview
 - 16.2.2. Company Snapshot
 - 16.2.3. Products & Services
 - 16.2.4. Financials (In case of listed companies)
 - 16.2.5. Recent Developments
 - 16.2.6. SWOT Analysis
- 16.3. Epic Pharma LLC
 - 16.3.1. Business Overview
 - 16.3.2. Company Snapshot
 - 16.3.3. Products & Services
 - 16.3.4. Financials (In case of listed companies)
 - 16.3.5. Recent Developments
 - 16.3.6. SWOT Analysis
- 16.4. F. Hoffmann La Roche Ltd.
 - 16.4.1. Business Overview
 - 16.4.2. Company Snapshot
 - 16.4.3. Products & Services
 - 16.4.4. Financials (In case of listed companies)
 - 16.4.5. Recent Developments
 - 16.4.6. SWOT Analysis
- 16.5. GlaxoSmithKline Plc
 - 16.5.1. Business Overview
 - 16.5.2. Company Snapshot
 - 16.5.3. Products & Services
 - 16.5.4. Financials (In case of listed companies)
 - 16.5.5. Recent Developments
 - 16.5.6. SWOT Analysis
- 16.6. Intas Pharmaceuticals Ltd.
 - 16.6.1. Business Overview
 - 16.6.2. Company Snapshot
 - 16.6.3. Products & Services
 - 16.6.4. Financials (In case of listed companies)

- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
- 16.7. Jubilant Pharmova Ltd.
 - 16.7.1. Business Overview
 - 16.7.2. Company Snapshot
 - 16.7.3. Products & Services
 - 16.7.4. Financials (In case of listed companies)
 - 16.7.5. Recent Developments
 - 16.7.6. SWOT Analysis
- 16.8. Lupin Ltd.
 - 16.8.1. Business Overview
 - 16.8.2. Company Snapshot
 - 16.8.3. Products & Services
 - 16.8.4. Financials (In case of listed companies)
 - 16.8.5. Recent Developments
 - 16.8.6. SWOT Analysis
- 16.9. Novartis AG
 - 16.9.1. Business Overview
 - 16.9.2. Company Snapshot
 - 16.9.3. Products & Services
 - 16.9.4. Financials (In case of listed companies)
 - 16.9.5. Recent Developments
 - 16.9.6. SWOT Analysis
- 16.10. Pfizer Inc.
 - 16.10.1. Business Overview
 - 16.10.2. Company Snapshot
 - 16.10.3. Products & Services
 - 16.10.4. Financials (In case of listed companies)
 - 16.10.5. Recent Developments
 - 16.10.6. SWOT Analysis

17. STRATEGIC RECOMMENDATIONS

18. ABOUT US & DISCLAIMER

I would like to order

Product name: Vertigo Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Peripheral vertigo, Central vertigo), by Distribution Channel (Offline, Online), by region, and Competition

Product link: <https://marketpublishers.com/r/VC9C4A5D8529EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VC9C4A5D8529EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970